Literature DB >> 30872203

Different Techniques of Minimally Invasive Craniopuncture for the Treatment of Hypertensive Intracerebral Hemorrhage.

Lei Xia1, Qiu Han2, Xiao-Yu Ni3, Bing Chen3, Xiu Yang3, Quan Chen3, Guan-Liang Cheng3, Chun-Feng Liu4.   

Abstract

OBJECTIVE: Efficacy of minimally invasive craniopuncture with the YL-1 puncture needle (hard-channel) and soft drainage tube (soft-channel) in treating hypertensive intracerebral hemorrhage (HICH).
MATERIALS AND METHODS: A total of 150 patients with HICH were randomly assigned into 3 groups: conservative group (n = 50), hard-channel group (n = 50), and soft-channel group (n = 50). Computed tomography, National Institutes of Health Stroke Scale (NIHSS) and the levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), superoxide dismutase (SOD), and malondialdehyde (MDA) in serum and in drainage fluid were examined on days 2, 4, and 6 after operation.
RESULTS: Compared with the conservative group, the serum levels of IL-6, TNF-α, and MDA were decreased and SOD was increased (P < 0.05); volumes of hematoma and perihematomal edema as well as NIHSS were reduced (P < 0.05) in minimally invasive groups on days 7, 14, and 28 after operation. Compared with the hard-channel group, the serum levels of IL-6, TNF-α, MDA, and SOD showed the same trend as above in the soft-channel group. In the soft-channel group, MDA was reduced and SOD was increased in brain drainage fluid on days 2, 4, and 6 (P < 0.05); volumes of hematoma and perihematomal edema on days 14 and 28 were found to be reduced compared with the hard-channel group (P < 0.05). There was no significant difference of volumes of hematoma and perihematomal edema on day 7 between minimally invasive groups. NIHSS of the soft-channel group appeared to be significantly reduced on days 7, 14, and 28 after operation (P < 0.05).
CONCLUSIONS: Soft-channel minimally invasive craniopuncture is an ideal technique for treating HICH, with advantages of alleviating cerebral edema, reducing oxidative stress, and inhibiting inflammatory response.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brain injury; Hypertension; Intracerebral hemorrhage; Minimally invasive; Soft-channel

Mesh:

Substances:

Year:  2019        PMID: 30872203     DOI: 10.1016/j.wneu.2019.03.006

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

Review 1.  Minimally Invasive Intracerebral Hemorrhage Evacuation: A review.

Authors:  Mishek J Musa; Austin B Carpenter; Christopher Kellner; Dimitri Sigounas; Isuru Godage; Saikat Sengupta; Chima Oluigbo; Kevin Cleary; Yue Chen
Journal:  Ann Biomed Eng       Date:  2022-02-28       Impact factor: 3.934

2.  Analysis of the Therapeutic Effect and Prognostic Factors of 126 Patients With Hypertensive Cerebral Hemorrhage Treated by Soft-Channel Minimally Invasive Puncture and Drainage.

Authors:  Jiaxun Wu; Sunfu Zhang
Journal:  Front Surg       Date:  2022-04-29

3.  Low-Cost, Accurate, Effective Treatment of Hypertensive Cerebral Hemorrhage With Three-Dimensional Printing Technology.

Authors:  Ke Li; Xiangqian Ding; Qingbo Wang; Gangxian Fan; Wei Guo; Chenglong Li; Meng Li; Zefu Li
Journal:  Front Neurol       Date:  2021-02-25       Impact factor: 4.003

4.  The Effect of Hemoglobin Concentration on Hyperbaric Oxygen and Non-hyperbaric Oxygen in the Treatment of Hypertensive Intracerebral Hemorrhage After Operation at the High Altitude.

Authors:  Linjie Wei; Chi Lin; Xingsen Xue; Shiju Jila; Yalan Dai; Li Pan; Wei Wei; Guodong Dun; Yong Shen; Taoxi Zong; Jingjing Wu; Yafang Li; Lixia Wu; Jishu Xian; Anyong Yu
Journal:  Front Hum Neurosci       Date:  2022-06-30       Impact factor: 3.473

Review 5.  Molecular, Pathological, Clinical, and Therapeutic Aspects of Perihematomal Edema in Different Stages of Intracerebral Hemorrhage.

Authors:  Chao Jiang; Hengtao Guo; Zhiying Zhang; Yali Wang; Simon Liu; Jonathan Lai; Tom J Wang; Shize Li; Jing Zhang; Li Zhu; Peiji Fu; Jiewen Zhang; Jian Wang
Journal:  Oxid Med Cell Longev       Date:  2022-09-17       Impact factor: 7.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.